Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-sirolimus and Fulvestrant in Recurrent Low Grade Serous Ovarian Cancer
NCT06494150Phase 2Active, not recruiting
- Sponsor
- University of Oklahoma
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-sirolimus in Low grade serous ovarian cancer (LGSOC), sponsored by University of Oklahoma. Started Dec 2024; status: active, not recruiting.
02
Drugs
nab-sirolimus
03
Conditions
Low grade serous ovarian cancer (LGSOC)
Beyond the preview
Go deeper on NCT06494150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494150.